BetterLife Pharma (TSE:BETR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BetterLife Pharma Inc. has amended beneficial ownership information in past Management Information Circulars and announced the issuance of new shares and warrants following a convertible debentures conversion. The biotech company is advancing the development of non-hallucinogenic compounds, BETR-001 and BETR-002, aimed at treating various neuropsychiatric and neurological disorders.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
